Organization
Baylor University Medical Center
19 abstracts
Abstract
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Tennessee Oncology, PLLC, University General Hospital of Heraklion, Hospital de Cancer de Londrina, Baskent University Faculty of Medicine, Mater Adult Hospital Brisbane,
Abstract
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.Org: University of Kansas Cancer Center, GZA ANTWERP BELGIUM, Texas Oncology, University of Kansas Medical Center, University of Kansas Medical Center Department of Internal Medicine,
Abstract
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.Org: Weill Cornell Medical College - New York Presbyterian Hospital, Fox Chase Cancer Center, Arnie Charbonneau Cancer Institute, University of Calgary, Massachusetts General Hospital Cancer Center, Pfizer SLU,
Abstract
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.Org: Yale Cancer Center, Yale School of Medicine, Emory University School of Medicine, Nashville Breast Center, Dallas Surgical Group,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients.Org: Baylor University Medical Center, Dallas, TX,
Abstract
A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Baylor University Medical Center, Texas Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Radical prostatectomy versus XRT for early-stage prostate cancer: A retrospective, propensity-matched cohort study of 29,970 patients.Org: Baylor University Medical Center, Alara Medical Group,
Abstract
Chemoradiation versus cystectomy for locally advanced bladder cancer: A global, propensity-matched retrospective cohort study.Org: Alara Medical Group, Baylor University Medical Center,
Abstract
Enhancing non-small cell lung cancer treatment utilizing natural killer cell-derived extracellular vesicles (NKEVs) as a novel adoptive cellular therapeutic.Org: Tgen, Baylor University Medical Center,
Abstract
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fox Chase Cancer Center, David Geffen School of Medicine at UCLA, Winship Cancer Institute at Emory University, Georgetown University Medical School,
Abstract
Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB–IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists.Org: Cardinal Health, Baylor University Medical Center,
Abstract
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.Org: Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute, Florida Cancer Specialists and Research Institute, Ocala, FL, Memorial Sloan Kettering Cancer Center,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).Org: Northwestern University Feinberg School of Medicine, Northwestern Medicine Devleopmental Therapeutics Institute, Northwestern Memorial Hospital, Chicago, IL, AMITA Health Saint Francis Hospital Evanston, Kyungpook National University Hospital,
Abstract
A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.Org: Hoag Family Cancer Institute and University of Southern California, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Buzzard Pharmaceuticals AB, Buzzard Pharmaceuticals,
Abstract
Quality care of patients with HR+/HER2- breast cancer: Insights from an implementation science program.Org: PRIME Education LLC, Baylor University Medical Center, Texas Oncology, US Oncology Research,